Friday, 21 Sep 2018

You are here

Inefficacy of Immunosuppressive Treatments in Systemic Sclerosis with ILD

EUSTAR study results published in Arthritis Research & Therapy show the current state of immunosuppressive use in systemic sclerosis patients with interstitial lung disease (SSc-ILD) to be ill-defined, but that liberal use of glucocorticoids (GC) in SSc-ILD should be discouraged.

The EUSTAR study group analyzed 11,496 patients with SSc, of whom 3778 had ILD (33%). Nearly 71% were treated with immunosuppresives (IS) and glucocorticoid (GC) were used by 58% patients. Only 29% had never been treated with IS.

GC were often combined with various DMARDs, including cyclophosphamide (CYC) (11.9%), azathioprine (AZA) (9.2%), methotrexate (MTX) (8.7%), or mycophenolate mofetil (MMF) (7.3%).

Intensive IS (MMF + GC, CYC or CYC + GC) was started in patients with the worst PFTs and ground glass opacifications on imaging.

Patients who received IS where younger, had shorter disease durations, higher Rodnan skin scores, had more diffuse skin disease, more active disease, worse DLCO and FVC values and were more likely to be Scl-70 antibody positive.

No specific types of IS was clearly superior to another in influencing the course of lung function. 

Effective therapy for SSc-ILD patients continues to be a significant unmet need. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

An Association between GCA and IBD ?

A population based analysis from Israel suggests that giant cell arteritis (GCA) patients may be at increased risk for  inflammatory bowel diseases (IBD) mainly target.

This research was based on sporadic reports in the medical literature (http://bit.ly/2pnIPM0)

Breast Implant Study: More Worries or Not?

The Annals of Surgery reports on an anlaysis of FDA-mandated postmarket studies, including nearly 100,000 breast implant pprocedures, that showed silicone implants to be associated with higher rates of  Sjögren's syndrome, scleroderma, rheumatoid arthritis, stillbirth, and melanoma.

New Classification of Idiopathic Inflammatory Myopathies

Using an observational cohort analysis of patients in the French myositis network, researchers have proposed a new classification of idiopathic inflammatory myopathies (IIM) with four subgroups: dermatomyositis, inclusion body myositis, immune-mediated necrotizing myopathy, and antisynthetase syndrome.

Rsearchers set out to define a classification system for IIM based on phenotypic, biological, and immunologic criteria. 

Depression Increases Risk of Systemic Lupus Erythematosus

Twenty-year data from the Nurses’ Health Study (NHS) suggests that depression is associated with a 2-fold increased frequency of systemic lupus erythematosus (SLE) - the question is why?

Interferon Blocker Disappoints in SLE

Yet another setback has occurred in the efforts to develop new medications for treating systemic lupus erythematosus (SLE), as anifrolumab failed to meet the primary endpoint in a phase III trial, according to AstraZeneca and MedImmune.